Illumina (ILMN) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Illumina (ILMN) has outperformed Natera (NTRA) over the past year, gaining 180.9% versus a gain of 137.9%. Over five years, NTRA leads with a +261.9% price change compared with -31.9% for ILMN. Natera is the larger company by market cap ($57.02 billion vs $40.43 billion), about 1.4 times the size.
Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ILMN | NTRA |
|---|---|---|
| Share price | $267.76 | $395.56 |
| Market cap | $40.43B | $57.02B |
| 1-day change | -2.11% | -1.27% |
| YTD return | +107.05% | +74.97% |
| 1-year return | +180.89% | +137.85% |
| 5-year return | -31.90% | +261.88% |
| P/E ratio (TTM) | 49.96 | — |
| Forward P/E | 43.83 | — |
| EPS (TTM) | $5.36 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.34B | $2.31B |
| Revenue growth (YoY) | -0.66% | +35.90% |
| Net income (latest FY) | $850.00M | $-208.16M |
| Gross margin | 66.08% | — |
| Operating margin | 18.58% | -13.44% |
| Net margin | 19.57% | -9.03% |
| 52-week high | $309.35 | $437.41 |
| 52-week low | $88.00 | $167.99 |
| Distance from 52-week high | -13.44% | -9.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -16.40% | -4.58% |
| Average volume | 2.66M | 1.42M |
| Shares outstanding | 151.00M | 144.14M |
| Employees | 8,600 | 6,135 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed NTRA by 43.0 percentage points over the past year.
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs -0.66%).
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Healthcare · Diagnostics & Research · 8,600 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Healthcare · Diagnostics & Research · 6,135 employees
ILMN vs NTRA FAQ
Which is bigger, Illumina or Natera?
Natera (NTRA) is larger, with a market capitalization of $57.02B compared with $40.43B for Illumina (ILMN).
Which stock has performed better over the past year, ILMN or NTRA?
ILMN returned +180.89% over the past 12 months, compared with +137.85% for NTRA (price return, excluding dividends). Past performance does not predict future results.
Are Illumina and Natera in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.